IL1RAP Blockade With a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis
Blocking IL1RAP reduces acute CVB3 myocarditis and EAM severity and preserves cardiac function in EAM. We conclude that IL1RAP blockade is a potential therapeutic strategy in viral and autoimmune myocarditis.
Authors
- Elin Jaensson Gyllenbäck (ORCID: https://orcid.org/0000-0002-1334-8642)
- Hannah Kalinoski (ORCID: https://orcid.org/0000-0002-2732-0077)
- Caitríona Grönberg (ORCID: https://orcid.org/0009-0000-3776-5566)
- Alexandru Șchiopu (ORCID: https://orcid.org/0000-0002-7587-5050)
- Gabriel Jakobsson (ORCID: https://orcid.org/0000-0001-5071-9505)
- Nadan Wang (ORCID: https://orcid.org/0000-0002-1682-080X)
- Sara Rattik (ORCID: https://orcid.org/0000-0002-5172-6456)
- David S. Elias (ORCID: https://orcid.org/0000-0002-4363-3057)
- Diego Lema (ORCID: https://orcid.org/0000-0001-7910-1127)
- Daniela Čiháková (ORCID: https://orcid.org/0000-0002-8713-2860)
- Abdel Daoud (ORCID: https://orcid.org/0009-0004-6661-5670)
- David Liberg (ORCID: https://orcid.org/0009-0009-0645-746X)
- Monica V. Talor (ORCID: https://orcid.org/0000-0002-8275-5698)
Institutions
- Canon (Japan) (JP)
- Johns Hopkins University (US)
- Malmö University (SE)
- Lund University (SE)
- Johns Hopkins Medicine (US)
- Skåne University Hospital (SE)
- Institute of Parasitology (CZ)
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1161/circheartfailure.124.011729
- Citations
- 8
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Johns Hopkins University
- National Institutes of Health